Management of suspected acute heart failure dyspnea in the emergency department: results from the French prospective multicenter DeFSSICA survey by unknown
ORIGINAL RESEARCH Open Access
Management of suspected acute heart
failure dyspnea in the emergency
department: results from the French
prospective multicenter DeFSSICA survey
Tahar Chouihed1,2,3,4, Stéphane Manzo-Silberman5,6, Nicolas Peschanski7,8, Sandrine Charpentier9,10,11,
Meyer Elbaz12, Dominique Savary13, Eric Bonnefoy-Cudraz14, Said Laribi5,6, Patrick Henry6,15, Nicolas Girerd2,3,
Faiez Zannad2,3 and Carlos El Khoury16,17*
Abstract
Background: An appropriate diagnostic process is crucial for managing patients with acute heart failure (AHF) in
emergency department (ED). Our study aims to describe the characteristics and therapeutic management of patients
admitted to the ED for dyspnea suspected to have AHF, their in-hospital pathway of care and their in-hospital outcome.
Methods: Consecutive patients admitted in 26 French ED for dyspnea suspected to be the consequence of AHF, prior
to in hospital diagnostic test, were prospectively included at the time of their admission in the DeFSSICA Survey. Clinical
characteristics at admission were recorded by the ED physicians. At discharge from ED, patients were categorized as
AHF or non-AHF based on the final diagnosis reported in the discharge summary. The completeness of the data was
controlled by the local investigator.
Results: From 16/6/2014 to 7/7/2014, 699 patients were included, of whom 537 (77 %) had a final diagnosis of AHF
at discharge. Patients with AHF were older (median 83 vs 79 years, p = 0.0007), more likely to have hypertension
(71 % vs 57 %, p = 0.002), chronic HF (54 % vs 37 %, p = 0.0004), atrial fibrillation (45 % vs 34 %, p = 0.02) and history
of hospitalization for AHF in the previous year (40 % vs 18 %, p < 0.0001) when compared to patients without AHF.
Furosemide and oxygen were used in approximately 2/3 of the patients in the ED (respectively 75 and 68 %)
whereas nitrates were in 19 % of the patients. Diagnostic methods used to confirm AHF included biochemistry
(100 %), pro-B-type natriuretic peptide (90 %), electrocardiography (98 %), chest X-ray (94 %), and echography
(15 %) which only 18 % of lung ultrasound.
After the ED visit, 13 % of AHF patients were transferred to the intensive care unit, 28 % in cardiology units and
12 % in geriatric units. In-hospital mortality was lower in AHF vs non-AHF patients (5.6 % vs 14 %, p = 0.003).
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Discussion: DeFSSICA, a large French observational survey of acute HF, provides information on HF presentation
and the French pathway of care. Patients in DeFSSICA were elderly, with a median age of 83 years. Compared with
the French OFICA study, patients in DeFSSICA were more likely to have hypertension (71 % vs 62 %) and atrial
fibrillation (45 % vs 38 %). As atrial fibrillation and a rapid heart rate have been closely linked to mortality, detection
of atrial fibrillation should be considered systematically.The limited use of nitrates in DeFSSICA may be related to
the median SBP of 140 (121–160) mmHg. However, our use of nitrates was similar to those in the EAHFE (20.7 %)
and OPTIMIZE-HF (14.3 %) registries. In line with guidelines, the proportions of patients who underwent ECG,
biological analysis, or chest X-ray were all >90 % in DeFSSICA. Similarly, BNP or pro-BNP was measured in 93 % of
patients, compared with 82 % of patients in the OFICA study. Although BNP may be helpful when the diagnosis of
HF is in doubt, ultrasound remains the gold standard. The use of ultrasound in the ED has been reported to
accelerate the diagnosis of HF and the initiation of treatment, and shorten the length of stay. In-hospital mortality
of HF patients in DeFSSICA was 6.4 %, slightly lower than in the OFICA study (8.2 %). Improved interdisciplinary
cooperation has been highlighted as a key factor for the improvement of HF patient care.
Conclusions: DeFSSICA shows that patients admitted for dyspnea suspected to be the consequence of AHF are
mostly elderly. The diagnosis of AHF is difficult to ascertain based on clinical presentation in patients with dyspnea.
Novel diagnostic techniques such as thoracic ultrasound are warranted to provide the right treatment to the right
patients in the ED as early as possible.
Background
Heart failure (HF) has been estimated to affect approxi-
mately 2 % of adults in developed countries [1], and 9 % of
those aged 80–89 years [2]. HF is the cause of over 150,000
hospitalizations in France each year, and the costs of treat-
ing patients with HF have been estimated to consume
around 1 % of the total healthcare costs [2]. Patients with
HF often present in acute or subacute decompensation in
acute HF, but various other conditions can also cause dys-
pnea, raising the problem of differential diagnosis.
Importance
An appropriate diagnostic process is crucial for starting
the patient on the right care pathway and to avoid loss
of time in care. However, no trial or survey has de-
scribed the current management of acute HF syndromes
in the French emergency medical system.
Goals of this investigation
The main objective was to assess the diagnostic and thera-
peutic management of emergency patients with suspected
heart failure dyspnea. Secondary objectives were to define
the pathway of care according to the Emergency Depart-
ment (ED) diagnosis and evaluate mortality.
Methods
Study design and setting
DeFSSICA (Description de la Filière de Soins dans les
Syndromes d’Insuffisance Cardiaque Aigue) is a French
prospective survey that recruited consecutive patients
presenting with suspected heart failure dyspnea in 26
emergency departments (EDs) in academic hospitals and
community and regional hospitals. The study was
promoted by the French Society of Cardiology (Société
Française de Cardiologie [SFC]), the French Society of
Emergency Medicine (Société Française de Médecine
d'Urgence [SFMU]) and RESCUe (an emergency cardio-
vascular network).
DeFSSICA received approval from the National Com-
mission for Liberties and Data Protection (Commission
Nationale de l’Informatique et des Libertés [CNIL]) (num-
ber DR-2014-543) and the Advisory Committee on the
Treatment of Information in the field of Health Research
(Comité Consultatif sur le Traitement de l’Information en
matière de Recherche dans le domaine de la Santé
[CCTIRS]) (number 14-291). All patients received written
information about the survey objectives.
Selection of participants
Consecutive patients aged above 18 years admitted to the
ED with dyspnea compatible with acute HF were included
in the survey by the emergency physician on charge and
prior to chest X-ray and laboratory test. Dyspnea com-
patible with HF was defined as dyspnea associated with
peripheral edema and/or pulmonary crackles and/or ex-
cessive weight gain and/or use of furosemide.
Methods and measurements
Data concerning baseline characteristics, medical his-
tory, social factors, in-hospital diagnostic tests and treat-
ment, final diagnosis, destination after ED discharge, and
in-hospital mortality and length of stay were recorded by
emergency physicians in a case report form (CRF). The
CRF was structured according to the progress of care.
Cardiac sonographic evaluations were judged at the sole
discretion of emergency physician. Abnormal chest ray
was defined by the presence of cardiomegaly and/or
alveolar edema and/or interstitial opacity and/or pleural
effusion. The choice of treatment was at the emergency
physician’s discretion, according to their usual practice.
Final diagnosis of acute HF was retained by emergency
physician as a combination of a clinical history, an
abnormal chest x-ray, an elevated BNP/proBNP and
ultrasound signs. Data were entered into a secured data-
base located at the RESCUe Coordination Center.
Chouihed et al. Scandinavian Journal of Trauma, Resuscitation and Emergency Medicine  (2016) 24:112 Page 2 of 10
Local investigators monitored the data to check for
any errors or inconsistencies. They were also in charge
of trying to recover missing data. At discharge from ED,
patients were categorized as AHF or non-AHF based on
the final diagnosis reported in the discharge summary.
A hotline staffed by a clinical research assistant was
dedicated to the survey (during the daytime).
Outcomes
This study examined the pathway of care (from transporta-
tion to the ED to discharge destination); the use of various
diagnostic methods (biological and imaging) and treatments;
clinical signs and symptoms; causes of HF; and mortality.
Analysis
All patients with suspected heart failure dyspnea were
included. Comparisons between those with and without
a final diagnosis of HF were undertaken. Data are me-
dians and interquartile ranges (IQRs) for continuous
variables, and numbers and percentages for qualitative
variables. Comparative analyses were performed using the
χ2 or Fisher’s test for binary variables and the Wilcoxon
test for analysis of variance for continuous variables. Dif-
ferences were considered to be statistically significant
when the P value was <0.05. Analysis were performed
using the R statistical package.
Results
Characteristics of study subjects
Between June 16 and July 7, 2014, DeFSSICA recorded
699 cases of suspected cardiac dyspnea, of whom 537
(77 %) were ultimately identified as having HF. During
the same period, 64,281 emergency visits were recorded,
thus HF accounted for 0.8 % of ED visits.
Thirteen (50 %) investigators centers were academic
hospitals, 11 (42 %) were community hospitals and 2
(8 %) of them were regional hospitals. The academic
hospitals included 349 (50 %) patients, community hos-
pitals included 243 (35 %) patients and regional hospitals
included 107 (15 %).
Baseline characteristics of patients with and without
an ED diagnosis of HF are shown in Table 1. HF patients
were older than those without HF, and just under half of
each group were male. HF patients were significantly
more likely to have hypertension, chronic heart failure,
and atrial fibrillation than patients without HF, but the
prevalence of other comorbidities did not differ between
the two groups. HF patients were more likely to be taking
furosemide, angiotensin-converting enzyme inhibitors
(ACEIs) or angiotensin II receptor blockers (ARBs), β-
blockers, anticoagulants, and insulin than those without
HF. Compared to those without HF, those with HF were
more likely to have been hospitalized for HF at least once
during the past year; they were also more likely to be
under the care of a cardiologist.
Most patients, with or without HF, were living at home
(Table 1). However, patients with HF were less likely to
be self-sufficient, and more likely to be in receipt of
home assistance.
Hospitalization and clinical status
Among all DeFSSICA patients, 63 % made their own
way to the ED (Table 2). For the remaining patients,
medical dispatch centers (Centres 15 or services d’aide
médicale urgente [SAMUs]) mobilized appropriate pre-
hospital assistance. There was no difference in the dis-
tribution of transport modes between patients with and
without HF.
Clinical signs were mainly similar between patients
with and without HF, but HF patients were more likely
to present with signs of right heart failure (Table 2).
Vital signs were also mainly similar between patients
with and without HF, although pulse oximetry was
lower among those with HF. Only 3.2 % of patients
with or without HF presented signs of cardiogenic
shock, while 54 and 18 % of HF patients were Killip 2
or 3, respectively, versus 29 and 9.4 %, respectively of
patients without HF (P < .0001).
Early management and diagnosis
At admission, all patients (100 %) underwent biological
analysis. Patients with HF had lower creatinine clearance
and higher B-type natriuretic peptide (BNP) and pro-
BNP (Table 3). Troponin was positive in 66 % of HF
patients versus 46 % in non-HF patients (P = .0001).
Most patients (98 %) underwent an ECG. HF patients
were more likely to have atrial fibrillation and left bundle
branch block (LBBB) (Table 4). The majority of patients
underwent chest X-ray (94 %), which was more often
abnormal in HF patients (95 % vs 71 %; P < .0001).
Echocardiography was performed in 104 patients
(15 %) of which 19 have received pulmonary echography.
Cardiologists conducted 60 % of echographies while
emergency physicians performed 40 % of them (Table 4).
Echographies performed by cardiologists were more
likely to be self-rated as satisfactory than those by
emergency physicians. Left ventricular ejection fraction
(LVEF) did not differ significantly between those with
and without HF.
Patients with HF were more likely to receive furosemide,
oxygen, and nitrates, but other emergency measures
occurred similarly in both groups (Table 4).
Among the 158 patients in whom the diagnosis of HF
was not retained, emergency physician reported pulmon-
ary disease in 51.3 % of them (mainly pulmonary infection,
pulmonary embolism, and chronic obstructive pulmonary
disease (COPD) exacerbation), cardiac disease in 29.1 %
(mainly acute coronary syndrome), unspecific diagnosis
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Table 1 Baseline characteristics of patients with suspected
cardiac dyspneaa
HF (n = 537) Not HF (n = 158) P
Age, y 83 (77–88) 79 (67–88) .00069
Men 235 (44) 76 (48) .38
Comorbidities
Hypertension 378 (71) 90 (57) .0015
Chronic heart failure 288 (54) 59 (37) .00035
Atrial fibrillation 239 (45) 54 (34) .023
Coronary heart disease 161 (30) 37 (23) .12
Diabetes mellitus 152 (28) 37 (23) .18
Chronic renal failure 120 (28) 30 (19) .41
Chronic respiratory failure 92 (17) 32 (20) .43
Known valvular disease 99 (19) 22 (16) .22
Prior medications
Furosemide 315 (59) 67 (43) .00059
ACEI/ARB 242 (45) 52 (36) .011
β-blocker 231 (43) 44 (28) .0010
Anticoagulant 236 (44) 48 (31) .0038
Aspirin 163 (31) 40 (26) .28
Other antiplatelet 61 (11) 16 (10) .80
Oral antidiabetic 71 (13) 19 (12) .83
Insulin 71 (13) 10 (6.3) .028
Amiodarone 58 (11) 19 (12) .74
Aldosterone antagonist 39 (7.3) 11 (6.9) .94
Digoxin 41 (7.6) 8 (5.1) .36
Thiazidine 34 (6.3) 12 (7.6) .68
None 29 (5.4) 19 (12) .0060
Unknown 13 (2.4) 7 (4.4) .28
Pacemaker
Single 18 (3.3) 4 (2.5) .81
Dual 39 (7.3) 9 (5.7) .63
Triple 7 (1.3) 1 (0.6) .80
Defibrillator 17 (3.2) 1 (0.6) .14
Prior hospitalization for HF during past year
0 301 (60) 123 (82) <.0001
1 136 (27) 17 (11) .00011
≥ 2 67 (13) 10 (6.6) .039
Followed by a cardiologist 367 (72) 92 (60) .0090
Residence .54
At home 445 (83) 124 (79)
Retirement institution 82 (15) 30 (19)
Other institution 8 (1.5) 3 (1.9)
Self-sufficient 273 (52) 98 (64) .012
Table 1 Baseline characteristics of patients with suspected
cardiac dyspneaa (Continued)
Home assistance
Housekeeper 157 (30) 27 (18) .0036
Family support 138 (26) 41 (27) .99
Nurse 129 (24) 21 (14) .0060
Known cognitive impairment 85 (16) 24 (15) .88
Bedridden 48 (8.99) 18 (12) .45
ACEI angiotensin-converting enzyme inhibitor, ARB angiotensin II receptor
blocker, HF heart failure, IQR interquartile range
aData are presented as n (%) or median (IQR). All percentages are out of patients
with non-missing data








Personal 342 (64) 99 (63) .81
Ambulance 91 (17) 30 (19) .35
Firemen 55 (10) 17 (11) .85
MICU 43 (8) 11 (7) .67
Inter-hospital transfer 6 (1) 1 (0.6) .59
Clinical signs .62
Warm extremities 414 (87) 124 (85)
Cold extremities 62 (13) 22 (15)
Signs of right heart failure 228 (43) 31 (20) <.0001
Inspiratory retraction 154 (29) 36 (23) .18
Inability to speak 45 (8.4) 11 (6.9) .67
First recorded vital signs
Heart rate, beats/min 85 (71–102) 81 (70–102) .41
SBP, mmHg 140 (121–160) 138 (118–155) .16
DBP, mmHg 75 (65–90) 74 (65–90) .43
SBP <100 mmHg 38 (7.0) 12 (7.6) .96
Respiratory rate, breaths/min 25 (20–30) 22 (19–30) .25
Pulse oximetry, % 94 (90–96) 95 (91–98) .032
GCS 15 (15–15) 15 (15–15) .89
Temperature, °C 37 (36–37) 37 (36–38) .052
Killip status <.0001
1 133 (25) 90 (59)
2 283 (55) 45 (29)
3 92 (18) 14 (9)
Signs of shock 17 (3.2) 4 (2.53)
DBP diastolic blood pressure, GCS Glasgow Coma Scale, HF heart failure, IQR
interquartile range, MICU mobile intensive care unit, SBP systolic
blood pressure
aData are presented as n (%) or median (IQR)
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Table 3 Biological and diagnostic testsa
HF (n = 537) Not HF (n = 158) P
Biological analysis
Performed 537 (100) 158 (100) 1
Sodium, mmol/L 138 (135–141) 138 (136–140) .69
Potassium, mmol/L 4.3 (4.0–4.7) 4.2 (3.9–4.7) .092
Creatinine clearance, mL/min 50 (35–69) 65 (42–92) <.0001
Creatinine clearance <30 mL/min 89 (17) 19 (14) .39
Hemoglobin, g/dL 12.4 (11.0–13.5) 13.2 (11.5–14.3) .15
Hemoglobin <10 g/dL 56 (11) 14 (8.9) .70
Troponin positive 282 (66) 56 (46) .00010
BNP,b ng/L 973 (502–2414) 338 (129–654) <.0001
Pro-BNP,c ng/L 4025 (1729–8863) 1281 (283–4818) <.0001
ECG
Performed 530 (99) 151 (96) .018
Sinusal 231 (44) 84 (56) .012
Atrial fibrillation 226 (43) 41 (27) .00073
Driven 48 (8.9) 15 (9.5) .87
AVB 23 (4.3) 12 (7.6) .12
LBBB 91 (17) 12 (7.6) .0076
RBBB 62 (12) 20 (13) .71
Repolarization disorder 107 (20) 32 (21) .88
Chest X-ray
Performed 511 (95) 129 (88) .0023
Abnormal 481 (95) 98 (71) <.0001
Cardiomegaly 252 (52) 51 (52) .96
Interstitial opacities 300 (62) 46 (47) .0047
Alveolar opacities 117 (24) 36 (37) .019
Echography
Performed 85 (16) 18 (11) .20
By cardiologist 48 (56) 13 (65) .33
Satisfactoryd 24 (60) 10 (91)
Intermediated 14 (35) 1 (9.1)
Weakd 2 (5.0) 0 (0)
By emergency physician 37 (44) 5 (35) .33
Satisfactoryd 6 (17) 2 (50)
Intermediated 20 (57) 2 (50)
Weakd 9 (26) 0 (0)
LVEFe .93
> 50 % 32 (41) 6 (43)
35–50 % 27 (34) 4 (29)
< 35 % 21 (26) 4 (29)
Dilated RV, n (%) 19 (32) 4 (36) .94
VC diameter, mm 20 (15–22) 15 (10–20) .38
AVB atrioventricular block, BNP brain natriuretic peptide, ECG electrocardiogram, HF heart failure, IQR interquartile range, IVC inferior vena cava, LBBB left bundle
branch block, LVEF left ventricular ejection fraction, RBBB right bundle branch block, RV right ventricle, US ultrasound
aData are presented as n (%) or median (IQR) and are among patients who underwent the relevant test and had non-missing data
bBNP was measured in 170 HF and 49 not HF patients
cPro-BNP was measured in 329 HF and 74 not HF patients
dSelf evaluation
eLVEF was measured in 80 HF and 14 not HF patients
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(discomfort, stress, panting or palpitation) in 10.7 %, renal
failure in 5.1 % and gastric disease in 3.8 %.
Outcomes
Most patients with suspected heart failure dyspnea had
acute HF (77 %). ED diagnosis (i.e. HF or NHF) was made
at the end of hospitalization by consulting the medical
record. Precipitating factors were not determined in
43 % of cases (Table 5). The most common determined
precipitating factors were infection (25 %) and
arrhythmia (15 %).
After the ED admission, HF patients were most likely
to be hospitalized in a cardiology ward, and only 13 %
required treatment in an intensive care unit (Table 5).
The destination unit was judged by the emergency phys-
ician as appropriate in 76 % of cases.
Only 1 % of patients died in the ED. In-hospital
mortality was lower among those with versus without
HF (5.6 % vs 14 %; P = .003), but length of stay was
longer (Table 5).
Discussion
This large French observational survey of acute HF coor-
dinated by emergency medicine investigators has success-
fully collected epidemiologic, diagnostic, and therapeutic
data, from emergency admission to hospital discharge. As
such, DeFSSICA provides information on HF presentation
and the French pathway of care.
Not surprisingly, patients in DeFSSICA were elderly,
with a median age of 83 years. However, DeFSSICA
patients were generally older than those in other HF regis-
tries from France (Observatoire Français de l’Insuffisance
Cardiaque Aiguë [OFICA]) [4], Switzerland (Acute Heart
Failure Global Survey of Standard Treatment [ALARM-
HF]) [5], Spain (Epidemiology of Acute Heart Failure in
Emergency Departments [EAHFE]) [6], and the US (Acute
Decompensated Heart Failure National Registry Emergency
Module [ADHERE-EM] [7], Organized Program to Initiate
Lifesaving Treatment in Hospitalized Patients with Heart
Failure [OPTIMIZE-HF]) [8]. Mean ages in these studies
ranged from 73 to 79 years (details of these registries
can be found in the Additional file 1). Compared with
these registries [4–8], patients in DeFSSICA were less
likely to have chronic respiratory failure or chronic HF,
but more likely to have chronic renal failure (Web
Appendix). Compared with the French OFICA study [4],
patients in DeFSSICA were more likely to have hyper-
tension (71 % vs 62 %) and atrial fibrillation (45 % vs
38 %). As atrial fibrillation and a rapid heart rate have
been closely linked to mortality [9], detection of atrial
fibrillation should be considered systematically.
Furosemide, oxygen, and nitrates were the most com-
monly used treatments in DeFSSICA patients with HF
(75, 68, and 19 %, respectively). The limited use of nitrates
may be related to the median (IQR) SBP of 140 (121–160)
mmHg. However, our use of nitrates was similar to those
in the EAHFE [6] (20.7 %) and OPTIMIZE-HF [8]
Table 4 Emergency treatment of patients with suspected
cardiac dyspneaa
HF (n = 537) Not HF (n = 158) P
Furosemide 395 (75) 45 (29) <.0001
Oxygen 360 (68) 68 (43) <.0001
Nitrates 101 (19) 11 (6.9) .00043
Anticoagulant 38 (7.0) 18 (11) .13
NIV/Boussignac CPAP 54 (10.0) 6 (3.8) .20
Antiarrythmics 25 (4.7) 8 (5.0) .96
Inotropic agents 3 (0.6) 1 (0.3) .61
Tracheal intubation 1 (0.2) 1 (0.3) .95
None 34 (6.3) 44 (28) <.0001
Data are presented as n (%)
CPAP continuous positive airway pressure, HF heart failure, NIV
non-invasive ventilation
aData are presented as n (%) or median (IQR) and are among patients who








Unknown 227 (43) NA NA
Infection 135 (25) NA NA
Rhythm disorder 81 (15) NA NA
Hypertension 57 (11) NA NA
Non-adherence to treatment 31 (5.8) NA NA
Acute coronary syndrome 23 (4.3) NA NA
Eating disorder 20 (3.7) NA NA
Diabetes decompensation 10 (1.9) NA NA
Discharge destination <.0001
Cardiology 150 (28) 16 (10)
Geriatric medicine 62 (12) 5 (3.2)
Other medical unit 105 (20) 45 (29)
Cardiology intensive care unit 67 (13) 15 (9.5)
Resuscitation unit 17 (3.2) 8 (5.1)
ED hospitalization unit 77 (14) 28 (18)
Back home 28 (5.2) 29 (19)
Other 28 (5.2) 11 (6.9)
Destination considered appropriate 405 (76) 123 (78) .59
Outcome
In-hospital mortality 30 (5.6) 21 (14) .0030
Still hospitalized at 30 days 34 (6.8) 4 (3.4) .13
Length of stay, days 7 (3–12) 5 (1–9) .00063
ED emergency department, HF heart failure, IQR interquartile range, NA
not applicable
aData are presented as n (%) or median (IQR). Percentages for whole table are
out of patients with non-missing data
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(14.3 %) registries. Only 10 % of our HF patients received
non-invasive ventilation or Boussignac continuous posi-
tive airway pressure (CPAP), similar to in the OFICA
study (12.4 %) [4]. This ventilation assistance improves
outcome in acute HF patients, especially those with
pulmonary edema [10, 11]. However, it requires patient
compliance and cooperation, which is not necessarily
obvious in elderly [12, 13].
Current recommendations for diagnostic investigations
in patients with suspected HF include first the assess-
ment of HF probability related to the clinical history
(history of coronary artery diseases, or hypertension, or
use of diuretics…), the physical examination (bilateral
ankle oedema, jugular venous dilatation…) and the ECG
(Class I, Level C) [14].
If one of these symptoms or abnormal ECG signs are
present, the measurement of BNP or NT-proBNP is the
second step in the algorithm of the diagnosis (Class IIa,
Level C) with also blood chemistry, and complete blood
count (Class I, Level C). Finally, comprehensive assess-
ment of patients with HF comprises, chest X-Ray, trans-
thoracic echocardiography (Class I, Level C), and lung
ultrasound (Classe IIb, Level C) [14]. However, in DeFS-
SICA, only 15 % of all patients underwent echography,
due to a lack of equipment and training of emergency
physicians. When echography was performed by a cardi-
ologist (60 % of cases), most considered the results to be
satisfactory (66 %), but when it was performed by emer-
gency physicians (40 % of cases), only 21 % considered
the results to be satisfactory. Therefore, we have identi-
fied a need for additional effort for training emergency
physicians and providing equipment, as prompt use of
echography in the ED has been shown to improve the
diagnosis of HF [15].
In line with guidelines, the proportions of patients
who underwent ECG, biological analysis, or chest X-ray
were all >90 % in DeFSSICA. Similarly, BNP or pro-BNP
was measured in 93 % of patients, compared with 82 %
of patients in the OFICA study [4]. Not surprisingly,
BNP and pro-BNP values were significantly higher
among those with versus without HF in DeFSSICA. Sev-
eral studies have shown the diagnostic and prognostic
values of BNP (and troponin) in HF [16–18]; however,
they have limited specificity and may be elevated sec-
ondary to a variety of causes [9]. Two recent papers have
also suggested that neprilysin [19] and soluble CD146
[20] may have a role in the diagnosis of acute HF.
Although BNP may be helpful when the diagnosis of HF
is in doubt [21], ultrasound remains the gold standard.
[22] The use of ultrasound in the ED has been reported
[23] to accelerate the diagnosis of HF and the initiation
of treatment, and shorten the length of stay. For ex-
ample, in this study [24] the use of ultrasound could
help early diagnosis and therapy for the patient who may
need to transfer to the intensive care unit and reduce
the length of stay for in-hospital patients. Several others
studies have shown the feasibility of ultrasound in the
ED and prehospital emergency management of HF
patients [24–27]. As the diagnosis of acute HF remains
difficult, ultrasound enables emergency physicians to
improve their diagnostic performance, optimize their
therapeutic strategy, and improve prognosis [28].. In the
DeFSSICA survey, only 19 patients received lung ultra-
sound (LUS) evaluation in the ED. This result clearly
shows that, for now, lung ultrasound is scarcely used by
French emergency physicians. This fact is really different
from the American or Italian practices where LUS is
being used frequently. Lung ultrasound is an excellent
differential diagnostic tool for distinguishing cardiac
causes from pulmonary causes of dyspnea [29].
Pivetta et al. [30] definitively confirmed the excellent
diagnostic performance of lung ultrasound to detect
acute HF in an ED setting. In their multicenter study
that included 1005 patients admitted with acute dyspnea,
LUS sensitivity and specificity were respectively 97 %
[95 % CI, 95–98.3 %] and 97.4 % [95 % CI, 95.7–98.6 %],
and were superior to the one observed with clinical evalu-
ation, chest X-ray and natriuretic peptides. Importantly,
the net reclassification index of the LUS-implemented
approach compared with standard workup was 19.1 %
[30], which suggest the high diagnostic value of LUS in
this setting. This performance of LUS has been confirmed
in a prehospital setting by Prosen et al. (100 % sensitivity,
95 % specificity) [31]. So it’s probably a key to extend the
training facilities for LUS in Europe, especially in France.
To date, the HF pathway of care has been poorly ex-
amined in the literature, in particular, patient destina-
tions after ED discharge. It has been suggested that up
to half of patients with HF may not require
hospitalization [32]. However, in DeFSSICA, 95 % of HF
patients were hospitalized, most commonly (28 %) in
cardiology units. Approximately 14 % of HF patients
were moved to ED hospitalization units, which provide
close observation in the absence of a bed in the appro-
priate unit, or for patients due to be discharged the
following day. Over one third of HF patients were hos-
pitalized in non-cardiology units, particularly geriatric
units (12 %). If the demonstration was made that the
management of HF patients is more optimal in cardi-
ology units [3], the choice of another destination may
have been governed by a lack of beds in cardiology
and/or the advanced age of some patients requiring a
geriatric unit. Considering that majority of patients
with AHF should be hospitalized in cardiology or ICU,
we asked emergency physicians to assess whether the
final destination was appropriate. In more than 75 % of
cases they considered it adapted based on the diagnosis
and the patient’s clinical status in ED. In 24 % of cases,
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the ED physician considered that the destination unit
was not appropriate, mainly due to lack of beds avail-
ability in the unit perceived as appropriate.
In DeFSSICA, 18 % of HF patients had creatinine
clearance <30 mL/min. Close cooperation with nephrolo-
gists is necessary in these patients, to determine whether
dialysis is indicated [28, 33].
Although the incidence of HF decreased between 2000
and 2010 in relation to improvements in the manage-
ment of myocardial infarction. Regarding to mortality,
we have different data between Europe and the United
States. While the mortality rate appears stable in the
United States between the years 2000-2010 [34], there is
a decrease between the years 1987–2008 in Europe [35].
In-hospital mortality of HF patients in DeFSSICA was
6.4 %, slightly lower than in the OFICA study [4]
(8.2 %). At 30 days, 6.8 % of DeFSSICA HF patients were
still hospitalized, while the median (IQR) length of stay
was 7 (3–12) days. In the same idea, the length of stay in
DeFSSICA is 7 days in median, like in EAHFE registry
[3] and ALARM-HF [5] study which include the patients
from the Emergency Department. However in OFICA
[4] registry the length of stay is twice. This is probably
explained by the inclusion of the patients admitted in in-
tensive cardiac unit who are probably more serious.
Improved interdisciplinary cooperation has been
highlighted as a key factor for the improvement of HF
patient care [36]. An acute HF syndromes clinical tri-
als network has been set up to improve clinical trials
in this patient population [37]. Telemedicine [38] and
wireless monitoring could also offer opportunities for
improved HF management.
Limitations
First, the DeFSSICA study was focused only on patients in
the ED. Additional prehospital data would be very valuable.
Our study has the strength and the limitation regard-
ing internal and external validity of its multicenter na-
tional design. We believe that data collection at different
settings, including academic, community, and regional
hospitals, makes the result of this study largely applic-
able to the French healthcare system.
We acknowledge that BNP was not available in every
patient despite the IIa European recommendation [14],
which is suboptimal. However, it is likely to reflect the
“real-life” use of BNP.
One of the limitations of our survey is that we only in-
cluded dyspneic patients with suspected HF origin, instead
of considering all dyspneic patients admitted to the ED.
Thus, we found that 23 % of patients don’t have HF.
Finally, a limitation of this survey is that the discharge
summary was not subject to expertise for the final
diagnosis.
Conclusion
In conclusion, DeFSSICA has provided insights into the
characteristics, diagnosis, treatment pathway, and out-
comes of patients with acute HF in French emergency
departments. As the diagnosis of AHF remains difficult,
Ultrasound enables emergency physicians to improve
their diagnostic performance, optimize their therapeutic
strategy and improve prognosis. Our study highlights
the need for the development of networks, such as those
that exist for acute coronary syndromes, for improving
the implementation of guidelines.
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